Mylan Recalls Amlodipine Besylate Tablets Due to Manufacturing Deviations
Mylan Pharmaceuticals is recalling Amlodipine Besylate Tablets, 2.5 mg, because they were not manufactured according to Good Manufacturing Practices.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. No specific injuries or illnesses are reported in the source text.
Plain-English summary
Mylan Pharmaceuticals Inc. is recalling Amlodipine Besylate Tablets, USP, 2.5 mg, in 90-count and 500-count bottles. The recall involves 37,752 bottles distributed nationwide and in Puerto Rico.
The recall was initiated because the pharmaceuticals were produced and distributed with active ingredients not manufactured according to Good Manufacturing Practices (CGMP Deviations). This classification is designated as Class II by the FDA.
Consumers with these products should contact their healthcare provider or pharmacist for guidance on alternative treatment options. The specific lot numbers affected are 3037907, 3040106, and 3044357.
The recalled product
- Product
- Amlodipine Besylate Tablets, USP, 2.5 mg, packaged in a) 90-count bottles (NDC 0378-5208-77) and b) 500-count bottles (NDC 0378-5208-05), Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A.
- Manufacturer
- Mylan Pharmaceuticals Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 37,752
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: a) 3037907
- 3040106
- b) 3037907
- 3044357
Distribution
Part of a larger recall action
This product is one of 12 recalled by Mylan Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 12 products in this recall →Related recalls
Same manufacturer · Mylan Pharmaceuticals Inc.
See all →- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Prasugrel Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-09
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- HighMycophenolate Mofetil Injection Recalled Due to Precipitate in Vials
FDA (Drugs) · 2026-08-05
- HighAmnesteem isotretinoin 40 mg capsules failed dissolution specifications
FDA (Drugs) · 2026-03-11
Same hazard · cgmp deviation
See all →- SevereBaxter Recalls Vasopressin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- HighBaxter Recalls Clindamycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
- ModerateLexia LLC Recalls Broadway Joe's Pain Cream Due to CGMP Deviations
FDA (Drugs) · 2026-09-09
- SevereBaxter Recalls Daptomycin Injection Due to Manufacturing Deviations
FDA (Drugs) · 2026-09-09
Similar recalls
- SevereMylan Amlodipine Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2016-08-31
- SevereMylan Amlodipine Besylate Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2016-08-31
- HighMylan Recalls Loxapine Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2018-05-30
- LowLupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-09-14
- SevereMylan Recalls Ciprofloxacin Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2015-01-28
- ModerateMylan Recalls Amlodipine and Benazapril Capsules Due to Cleaning Deviations
FDA (Drugs) · 2018-05-23